title: An inulin and doxorubicin conjugate for improving cancer therapy.
abstract: Chemotherapy is one of the primary treatment mechanisms for treating cancer. Current chemotherapy is systemically delivered and causes significant side effects; therefore the development of new chemotherapeutic agents or enhancing the effectiveness of current chemotherapeutic could prove vital to patients and cancer care. The purpose of this research was to develop a new conjugate composed of doxorubicin (chemotherapeutic) and inulin (polysaccharide chain) and evaluate its potential as a new therapeutic agent for cancer treatment. The synergistic effect of inulin conjugated to doxorubicin has allowed the same cytotoxic response to be maintained or improved at lower doses as compared to doxorubicin. Supporting results include cytotoxicity profiles, calf thymus DNA binding studies, confocal microscopy, and transport studies.
authors.affiliation: Department of Chemical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
authors.forename: C A
authors.initials: CA
authors.lastname: Schoener
authors.affiliation: Department of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
authors.forename: B
authors.initials: B
authors.lastname: Carillo-Conde
authors.affiliation: Department of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
authors.forename: H N
authors.initials: HN
authors.lastname: Hutson
authors.affiliation: Department of Chemical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA ; Department of Biomedical Engineering, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA ; College of Pharmacy, The University of Texas at Austin, 1 University Station, C0400, Austin, TX 78712, USA.
authors.forename: N A
authors.initials: NA
authors.lastname: Peppas
keywords: Conjugate; Cytotoxicity; Doxorubicin; Drug resistance; Inulin
references.citation: Semin Oncol. 1992 Dec;19(6):670-86
references.pmid: 1462166
references.citation: Gene Ther. 1995 Dec;2(10):702-9
references.pmid: 8750009
references.citation: Macromol Biosci. 2010 Mar 10;10(3):299-306
references.pmid: 20034125
references.citation: N Engl J Med. 2006 Sep 21;355(12):1253-61
references.pmid: 16990388
references.citation: Cell. 2011 Mar 4;144(5):646-74
references.pmid: 21376230
references.citation: Macromol Biosci. 2005 Nov 4;5(11):1074-84
references.pmid: 16245273
references.citation: Int J Pharm. 2001 Feb 1;213(1-2):143-52
references.pmid: 11165102
references.citation: Pharmacol Rev. 2004 Jun;56(2):185-229
references.pmid: 15169927
references.citation: Biotechnol Prog. 2002 May-Jun;18(3):612-6
references.pmid: 12052080
references.citation: Eur J Pharm Biopharm. 2004 Mar;57(2):163-9
references.pmid: 15018971
references.citation: Eur J Pharm Biopharm. 2004 May;57(3):447-55
references.pmid: 15093592
references.citation: Drug Intell Clin Pharm. 1985 Apr;19(4):259-64
references.pmid: 3891276
references.citation: Annu Rev Med. 2002;53:615-27
references.pmid: 11818492
references.citation: Carbohydr Res. 1995 Jul 10;271(1):101-12
references.pmid: 7648576
references.citation: Br J Nutr. 2005 Apr;93 Suppl 1:S73-90
references.pmid: 15877900
references.citation: Cancer Invest. 2001;19(4):424-36
references.pmid: 11405181
references.citation: Mol Cancer Ther. 2007 Nov;6(11):2985-94
references.pmid: 18025283
references.citation: J Hepatol. 2005 May;42(5):736-43
references.pmid: 15826724
references.citation: Acta Biochim Pol. 2002;49(1):145-55
references.pmid: 12136935
references.citation: Gastroenterology. 1989 Mar;96(3):736-49
references.pmid: 2914637
references.citation: Cancer Chemother Pharmacol. 1991;28(4):259-65
references.pmid: 1678995
references.citation: Am J Physiol. 1981 Oct;241(4):G275-88
references.pmid: 7032321
references.citation: Drug Discov Today. 2005 Mar 1;10(5):335-43
references.pmid: 15749282
references.citation: Nutr Cancer. 2000;38(1):1-5
references.pmid: 11341034
references.citation: J Pharmacol Exp Ther. 1992 Nov;263(2):762-6
references.pmid: 1359116
references.citation: J Control Release. 2002 Apr 23;80(1-3):197-205
references.pmid: 11943398
references.citation: Br J Nutr. 2002 May;87 Suppl 2:S273-81
references.pmid: 12088529
references.citation: J Nutr. 1999 Jul;129(7 Suppl):1402S-6S
references.pmid: 10395607
references.citation: J Gen Physiol. 1981 Oct;78(4):349-64
references.pmid: 7288392
references.citation: Biochemistry. 1990 Mar 13;29(10):2538-49
references.pmid: 2334681
references.citation: J Biomed Mater Res A. 2005 Mar 15;72(4):381-8
references.pmid: 15666363
references.citation: Int J Pharm. 2004 Apr 15;274(1-2):221-32
references.pmid: 15072798
references.citation: Drug Metab Dispos. 2004 Aug;32(8):794-9
references.pmid: 15258103
references.citation: Eur J Pharm Sci. 2006 Nov;29(3-4):183-97
references.pmid: 16777391
references.citation: Anticancer Drugs. 2000 Jun;11(5):377-84
references.pmid: 10912954
references.citation: Int J Pharm. 2008 Apr 16;354(1-2):143-8
references.pmid: 18262739
references.citation: J Pharm Sci. 2000 Jan;89(1):63-75
references.pmid: 10664539
references.citation: Pharm Res. 1997 Dec;14(12):1730-7
references.pmid: 9453061
references.citation: Scand J Clin Lab Invest. 1983 May;43(3):241-8
references.pmid: 6312556
references.citation: Methods Enzymol. 1985;112:285-98
references.pmid: 2413334
references.citation: Nature. 2001 Nov 1;414(6859):105-11
references.pmid: 11689955
references.citation: Cancer Causes Control. 1995 Mar;6(2):164-79
references.pmid: 7749056
references.citation: J Biomed Mater Res A. 2010 Feb;92(2):504-12
references.pmid: 19213059
references.citation: Cell. 2000 Jan 7;100(1):57-70
references.pmid: 10647931
references.citation: Nature. 2007 Jan 4;445(7123):106-10
references.pmid: 17122772
references.citation: J Biomater Sci Polym Ed. 2004;15(4):385-96
references.pmid: 15212324
references.citation: Acta Biomater. 2010 Jan;6(1):48-56
references.pmid: 19481619
references.citation: Cancer Res. 1998 Mar 1;58(5):947-55
references.pmid: 9500455